Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Innovative Industrial Properties Inc (IIPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Innovative Industrial Properties Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.01 (market cap $29.60B), while Innovative Industrial Properties Inc trades at $58.2 (market cap $1.67B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 17.7× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays a 13.18% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | IIPR | |
|---|---|---|
Market Cap | $29.60B | $1.67B |
Sector | Health | Real Estate |
52-Week High | $491.22 | $64.67 |
52-Week Low | $205.48 | $44.58 |
Enterprise Value | $27.56B | $2.21B |
Dividend Yield | — | 13.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
IIPR trades at $57.69, showing modest daily gains of 0.37%. The stock presents mixed signals with bearish technical indicators but strong fundamentals including a P/E of 13.05 and net margin of 52.27%. Recent Q2 2026 earnings beat expectations with $1.36 EPS versus $1.02 forecast. The company maintains robust cash flow from operations at $198.19M and recently declared a $1.90 dividend for H1-2026.
Outlook remains cautiously optimistic despite technical weakness. The 9.09% dividend yield and attractive valuation metrics provide support, but declining revenue from $266M (2025) to $264M (2026) and tenant concentration risks in the cannabis REIT sector warrant monitoring. Analyst consensus leans Hold (54.55%) with institutional interest growing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →
